Ontology highlight
ABSTRACT:
SUBMITTER: He Y
PROVIDER: S-EPMC6198883 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
He Yayi Y Cao Jie J Zhao Chao C Li Xuefei X Zhou Caicun C Hirsch Fred R FR
OncoTargets and therapy 20181016
Patients with malignant tumor treated with immunotherapy have received significant clinical benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4) and anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibodies, have produced impressive clinical results in different types of cancer. T-cell immunoglobulin and mucin domain-3 (TIM-3), another immune checkpoint, could inhibit cancer immunity. Recent studies have h ...[more]